Roger Song
Stock Analyst at Jefferies
(4.09)
# 368
Out of 5,182 analysts
58
Total ratings
44.9%
Success rate
18.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $58 → $71 | $53.31 | +33.19% | 4 | Apr 28, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $6 → $10 | $2.10 | +376.19% | 1 | Apr 15, 2026 | |
| REPL Replimune Group | Downgrades: Hold | $13 → $2 | $2.41 | -17.01% | 3 | Apr 13, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $8 → $16 | $4.07 | +293.12% | 4 | Mar 18, 2026 | |
| MANE Veradermics | Initiates: Buy | $75 | $101.00 | -25.74% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $16.77 | +269.71% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $258.20 | +43.69% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $98.27 | +20.08% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $14.29 | +193.91% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $82.50 | +46.67% | 12 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $68.10 | -33.92% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.37 | +117.10% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $432 → $564 | $569.75 | -1.01% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.45 | +244.83% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.76 | +2,136.84% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $28.15 | +27.89% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.37 | +337.96% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.08 | +127.27% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.04 | +269.32% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.73 | +220.73% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $4.32 | +62.04% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $65.96 | +34.93% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $7.72 | +223.83% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $16.38 | +150.31% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.42 | +100.92% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $57.03 | +126.20% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $98.85 | -1.87% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $31.20 | +252.56% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $2.62 | +1,235.88% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.19 | +114.80% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $35.75 | +487.41% | 1 | Sep 2, 2020 |
Kiniksa Pharmaceuticals International,
Apr 28, 2026
Maintains: Buy
Price Target: $58 → $71
Current: $53.31
Upside: +33.19%
Allogene Therapeutics
Apr 15, 2026
Maintains: Buy
Price Target: $6 → $10
Current: $2.10
Upside: +376.19%
Replimune Group
Apr 13, 2026
Downgrades: Hold
Price Target: $13 → $2
Current: $2.41
Upside: -17.01%
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $8 → $16
Current: $4.07
Upside: +293.12%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $101.00
Upside: -25.74%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $16.77
Upside: +269.71%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $258.20
Upside: +43.69%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $98.27
Upside: +20.08%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $14.29
Upside: +193.91%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $82.50
Upside: +46.67%
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $68.10
Upside: -33.92%
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.37
Upside: +117.10%
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $569.75
Upside: -1.01%
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.45
Upside: +244.83%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.76
Upside: +2,136.84%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $28.15
Upside: +27.89%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.37
Upside: +337.96%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.08
Upside: +127.27%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.04
Upside: +269.32%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.73
Upside: +220.73%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $4.32
Upside: +62.04%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $65.96
Upside: +34.93%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $7.72
Upside: +223.83%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $16.38
Upside: +150.31%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $17.42
Upside: +100.92%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $57.03
Upside: +126.20%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $98.85
Upside: -1.87%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $31.20
Upside: +252.56%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $2.62
Upside: +1,235.88%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $4.19
Upside: +114.80%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $35.75
Upside: +487.41%